A derivative from Utah-based Intermountain Well being has raised $10 million to carry longitudinal organic and medical knowledge to biopharmaceutical firms.
Fruits Bio says it maintains unique rights to a bodily library and cloud-based knowledge lake masking over 40 years of de-identified affected person digital well being data and biospecimen knowledge. This intensive knowledge lake can allow biopharmaceutical firms to realize insights essential to facilitating diagnostic and therapeutic growth.
The corporate notes that it could take over a decade and billions of {dollars} to acquire regulatory approval for therapies or diagnostic instruments. The issue begins with gaining access to longitudinal organic and medical affected person knowledge, which might take life sciences and biotech firms months to gather and course of.
With a constantly rising library of over 5 million de-identified affected person samples and medical knowledge spanning a long time, Fruits Bio can provide fast entry to retrospective affected person knowledge and sooner entry to hundreds of potential sufferers for research.
The $10 million funding is from Merck World Well being Innovation Fund and Amgen Ventures.
“With help from our traders, Fruits Bio is elevating the bar for healthcare innovation,” mentioned Lincoln Nadauld, M.D., Ph.D., president and CEO of Fruits Bio, in an announcement. He was beforehand vice chairman, chief of precision well being & teachers at Intermountain.
“On high of our current longitudinal affected person knowledge, we’re including over 300,000 biospecimens to our knowledge lake annually,” Nadauld added. “Due to this, we have now the flexibility to rapidly determine distinctive affected person cohorts from our huge knowledge lake that may velocity up essential analysis, resulting in novel discoveries..”
Along with rushing up affected person recruitment, the brand new firm mentioned the platform presents fast question capabilities throughout genomic, organic, medical, and claims knowledge, which has already supported analysis on all the pieces from population-wide genetic research to drug discovery.
“Fruits’s Intelligence Platform supplies collaborators with entry to uniquely wealthy de-identified medical datasets,” mentioned David M. Rubin, Ph.D., managing director at Merck World Well being Innovation Fund (GHIF), in an announcement. “GHIF seems ahead to working with the gifted and skilled Fruits administration staff to harness the ability of precision drugs to enhance outcomes for sufferers.”
